033 - SAFETY AND TOLERABILITY OF MYELOABLATIVE CONDITIONING AND AUTOLOGOUS STEM CELL TRANSPLANTATION FOLLOWED BY POLATUZUMAB VEDOTIN (PV) IMMNOCONJUGATE THERAPY IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA
| Autor: | Gardenswartz, A., Seiter, K., Hochberg, J., Morris, E., Harrison, L., Chu, Y., Basso, J., Gerard, P., Islam, H., Ayello, J., Cairo, M. |
|---|---|
| Zdroj: | In Leukemia Research October 2022 121 Supplement:S24-S25 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect